|Molecular Weight||598.1 g/mol|
|Shelf Life||3 years - 20°C powder|
|USP of Products||
Enclomiphene citrate exerts its effect on serum testosterone levels by elevating luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, while preserving semen parameters. This dual action, enhancing testosterone in men and concurrently safeguarding fertility, underscores the potential utility of Enclomiphene Citrate as a therapeutic option for individuals for whom testosterone therapy is not a suitable choice.
Description of Enclomiphene Citrate
Enclomiphene is an FDA approved medication for hypogonadism. While other exogenous testosterone therapy impairs sperm production, Enclomiphene citrate results in improved semen parameters indicative of improved probability and time to conception.
Application of Enclomiphene Citrate
- Treatment of Secondary Hypogonadism: Used in men for the treatment of secondary hypogonadism, which is a condition characterized by low testosterone levels due to problems with the hypothalamus or the pituitary gland.
- Male Infertility: Helps in treating certain cases of male infertility, particularly those associated with low testosterone levels and poor semen parameters.
- Testosterone Boosting: Acts to increase testosterone levels in men, which can be beneficial for various health issues related to testosterone deficiency.
- Gynecomastia Management: May be used in the management of gynecomastia (enlarged breast tissue in men) by balancing estrogen and testosterone levels.
- Obesity-Related Hypogonadism: Can be effective in treating hypogonadism that is associated with obesity, helping to improve hormonal balance.
- Metabolic Syndrome: There is interest in its potential for improving symptoms of metabolic syndrome in men, as it can positively affect testosterone levels and overall hormonal balance.
- Bodybuilding and Athletic Performance: Sometimes used off-label by bodybuilders and athletes to increase testosterone levels, although this is not a medically approved use and can have health risks.